
## STOP AF First

## #ESCCongress



**Trial Description:** Patients with paroxysmal atrial fibrillation were randomized to pulmonary vein isolation with cryoablation versus antiarrhythmic drug therapy.



## **RESULTS**

- Primary efficacy endpoint, freedom from efficacy failure at 12 months, occurred in 75% of the cryoballoon ablation group vs. 45% of the antiarrhythmic drug therapy group (p < 0.001)</li>
- The primary safety outcome at 12 months occurred in 1.9% of the cryoballoon ablation group vs. a performance goal of <12% (p < 0.0001)

## **CONCLUSIONS**

- Among patients with paroxysmal atrial fibrillation, a first-line cryoballoon ablation strategy was superior to antiarrhythmic drug therapy
- This strategy appeared to be safe with very few procedural-related adverse events

Presented by Dr. Oussama Wazni at ESC Virtual Congress 2020